Literature DB >> 19812966

Neuromodulation with pleiotropic and multimodal drugs -- future approaches to treatment of neurological disorders.

Dafin F Muresanu1.   

Abstract

Neurologists are confronted with an ever-growing amount of new information regarding the intimate processes taking place in both normal and pathological brains. Concepts like neuroprotection, neurotrophicity, or anoikis and their clinical utility may be of dazzling complexity. This paper briefly reviews some of the mechanisms involved in the pathogenesis of neurological diseases and current therapies. Since it is becoming more and more clear that using neuroprotective molecule with only one mechanism of action in disease treatment is a utopist idea, the research and use of multimodal drugs should be encouraged.It is not easy to find good therapeutic approaches to neurological disorders, especially if we do not have a deep understanding of all the basic endogenous biological processes, pathophysiological processes, and the links between them.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19812966     DOI: 10.1007/978-3-211-98811-4_54

Source DB:  PubMed          Journal:  Acta Neurochir Suppl        ISSN: 0065-1419


  8 in total

1.  Current Drug Treatment of Acute Ischemic Stroke: Challenges and Opportunities.

Authors:  Dafin F Muresanu; Stefan Strilciuc; Adina Stan
Journal:  CNS Drugs       Date:  2019-09       Impact factor: 5.749

2.  Brain recovery--an unified theory.

Authors:  Dafin F Mureşanu
Journal:  J Cell Mol Med       Date:  2010-01-30       Impact factor: 5.310

3.  2nd International Salzburg Conference on Neurorecovery (ISCN 2013) Salzburg/Austria|November 28th-29th, 2013.

Authors:  M Brainin; D Muresanu; D Slavoaca
Journal:  J Med Life       Date:  2014 Oct-Dec

4.  Cerebrolysin and early neurorehabilitation in patients with acute ischemic stroke: a prospective, randomized, placebo-controlled clinical study.

Authors:  A Stan; C Birle; A Blesneag; M Iancu
Journal:  J Med Life       Date:  2017 Oct-Dec

5.  Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials.

Authors:  Alla Guekht; Johannes Vester; Wolf-Dieter Heiss; Eugene Gusev; Volker Hoemberg; Volker W Rahlfs; Ovidiu Bajenaru; Bogdan O Popescu; Edith Doppler; Stefan Winter; Herbert Moessler; Dafin Muresanu
Journal:  Neurol Sci       Date:  2017-07-13       Impact factor: 3.307

6.  Current Synthesis and Systematic Review of Main Effects of Calf Blood Deproteinized Medicine (Actovegin®) in Ischemic Stroke.

Authors:  Florentina Carmen Firan; Aurelia Romila; Gelu Onose
Journal:  Int J Mol Sci       Date:  2020-04-30       Impact factor: 5.923

7.  Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial.

Authors:  Dafin F Muresanu; Wolf-Dieter Heiss; Volker Hoemberg; Ovidiu Bajenaru; Cristian Dinu Popescu; Johannes C Vester; Volker W Rahlfs; Edith Doppler; Dieter Meier; Herbert Moessler; Alla Guekht
Journal:  Stroke       Date:  2015-11-12       Impact factor: 7.914

Review 8.  Safety of Cerebrolysin for Neurorecovery after Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Twelve Randomized-Controlled Trials.

Authors:  Stefan Strilciuc; László Vécsei; Dana Boering; Aleš Pražnikar; Oliver Kaut; Peter Riederer; Leontino Battistin
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.